Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;70(7):502-5.
doi: 10.1016/j.humimm.2009.04.002. Epub 2009 Apr 11.

The role of positive flow cytometry crossmatch in late renal allograft loss

Ralph J Graff  1 , Huiling Xiao, Mark A Schnitzler, Patrick Ercole, Harvey Solomon, Tracy Pessin, Krista L Lentine
Affiliations

The role of positive flow cytometry crossmatch in late renal allograft loss

Ralph J Graff et al. Hum Immunol. 2009 Jul.

Abstract

Many studies relating flow cytometery crossmatch (FCXM) results to kidney transplant outcomes have examined risk in the first 3 to 12 months. We used Organ Procurement and Transplant Network registry data for 66,594 kidney transplants from 1995 to 2007 to investigate associations of T-cell positive (T+) and T-cell negative/B-cell positive (T(-)B+) FCXM with graft failure risk early (years 0-1) and late (years >1-5) after transplant. Compared with transplants with T-cell negative/B-cell negative (T(-)B(-)) FCXM, living-donor transplants performed after T+ FCXM had significantly higher adjusted, relative risks of both early (adjusted hazards ratio [aHR] 1.71, p < 0.0001) and late (aHR 1.36, p = 0.017) graft loss. T(-)B+ FCXM was associated with approximately 40% higher relative risk of graft loss in the late period only. Patterns were similar for deceased-donor transplants. The risks of positive FCXM persist beyond the peritransplant period for years after transplant. Damage by memory effector cells may explain the long-term risks associated with positive FCXM.

PubMed Disclaimer

Figures

Figure
Figure
Kaplan-Meier estimates of graft survival over five years according to FCXM results for living and deceased donor transplants.
See this image and copyright information in PMC

References

    1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–9. - PubMed
    1. Lentine KL, Graff RJ, Xiao H, Modanlou KA, Salvalaggio PR, Brennan DC, et al. Flow cytometry crossmatch before kidney transplantation in contemporary practice: Target cell utilization, results patterns, and associated long-term graft survival. Clin Transpl. 2008;Ch 23:253–66. - PubMed
    1. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant. 2003;3:1488–500. - PubMed
    1. Wilmonton-Hosey L, Chapman P, Holcomb J, Bray R. Flow cytometry crossmatch and antibody detection. ASHI Laboratory Manual. 2000:B.1.
    1. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation. 1990;49:527–35. - PubMed

Publication types

MeSH terms